In Vitro Efficacy Testing Services for Colon Cancer

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Colon Cancer. Our services offer comprehensive functional and mechanistic assays to evaluate candidate compounds, biologics, and immunotherapies targeting key molecular pathways in colon cancer. Critical targets include PD-1/PD-L1, CD274, and other immune checkpoint molecules, which play pivotal roles in tumor immune evasion. Our assays allow researchers to interrogate cellular proliferation, immune modulation, and apoptotic responses central to the pathogenesis and progression of colon cancer.

Our testing portfolio encompasses a diverse range of biochemical and cell-based assays designed to assess drug efficacy, mechanism of action, and immune interactions in vitro. These methods facilitate high-throughput screening, quantitative measurement of biological activity, and detailed molecular characterization. Collectively, they provide robust data to inform drug candidate selection and optimization.

ATP assay: Measures cellular ATP levels as an indicator of cell viability, proliferation, and cytotoxicity, providing a direct readout of compound efficacy.

CHO-K1 Chinese hamster ovary cells transfected with PDL1/OKT3: Serves as a model system to evaluate immune checkpoint modulation and antibody-mediated effects on PD-L1 expressing cells.

Chemiluminescent assay: Utilizes enzyme-catalyzed reactions generating light emission to sensitively quantify biological molecules or pathway activation.

Competitive binding assay (with CD274): Determines the binding affinity and specificity of test compounds to the CD274 (PD-L1) protein, crucial for immune checkpoint inhibitor assessment.

ELISA assay: A highly specific immunoassay to quantitatively measure proteins, cytokines, or antibodies relevant to colon cancer biology.

Fluorescent assay: Employs fluorescent dyes or probes to detect and quantify cellular or molecular events, enabling multiplexed analysis.

Fluorescent-activated cell sorting (FACS) assay: Enables detailed phenotypic and functional analysis of cell populations, including immune cell profiling and target engagement.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Combines FRET technology with time-resolved measurement for sensitive quantification of molecular interactions and signaling events.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT/luciferase: A reporter cell line for evaluating T-cell activation and the functional impact of immunomodulatory agents.

Luciferine/luciferase assay: Provides a luminescent signal proportional to cellular activity or gene expression, widely used for functional screening.

Surface plasmon resonance assay: Offers real-time, label-free measurement of biomolecular interactions, enabling detailed kinetic and affinity analysis of drug candidates.

We measure a suite of pharmacological parameters to quantitatively assess compound potency, efficacy, and binding characteristics. These metrics are fundamental for comparing candidate drugs and guiding optimization decisions. Accurate parameter determination is essential for predicting therapeutic potential and advancing compounds through preclinical development.

EC-50: The concentration of a compound that produces half-maximal effect, serving as a benchmark for drug potency.

IC-50: The concentration required to inhibit a biological process by 50%, commonly used to assess inhibitor effectiveness.

Kd: The equilibrium dissociation constant, reflecting the binding affinity between a drug and its target; lower Kd values indicate stronger binding.

MEC (Minimum Effective Concentration): The lowest concentration at which a compound elicits a measurable biological effect, important for dosing strategies.

MIC (Minimum Inhibitory Concentration): The lowest concentration of an agent that prevents visible growth of target cells, crucial for evaluating cytostatic or cytotoxic effects.

Recommended In Vitro Efficacy Tests

Dna Topoisomerase I

DNA Topoisomerase I regulates DNA supercoiling during replication and is often overexpressed in colon cancer, making it a key drug target. Testing its activity is crucial for evaluating drug efficacy and resistance. Key methods include relaxation assays and immunodetection. Main parameters assessed are enzyme activity, inhibition rate, and protein expression levels, providing essential data for colon cancer drug development and candidate screening.

Epidermal Growth Factor Receptor

Epidermal Growth Factor Receptor (EGFR) is a key driver of colon cancer progression and therapeutic resistance. EGFR testing is crucial for identifying drug response and guiding targeted therapy development. Our service employs surface plasmon resonance, FACS, fluorescent, and chemiluminescent assays to assess EGFR activity. Main parameters measured include MEC (Minimum Effective Concentration), IC-50 (half-maximal inhibitory concentration), MIC (Minimum Inhibitory Concentration), and Kd (dissociation constant) to evaluate drug efficacy and binding affinity.

Fibroblast Activation Protein Alpha

Fibroblast Activation Protein Alpha (FAPα) plays a key role in colon cancer progression by remodeling the tumor microenvironment. Accurate FAPα testing is vital for drug development targeting this pathway. Our service employs luciferin/luciferase, FACS, and surface plasmon resonance assays to evaluate drug interactions. We deliver critical parameters, including EC-50, Kd, and IC-50, supporting informed decision-making in colon cancer therapeutic development.

Programmed Cell Death 1

Our Programmed Cell Death 1 (PD-1) testing service supports colon cancer drug development by evaluating compounds targeting PD-1, a key immune checkpoint involved in tumor immune evasion. This testing is essential for identifying and characterizing anti-PD-1 therapeutics. We utilize advanced methods, including FACS, chemiluminescent and fluorescent assays, CHO-K1 and Jurkat cell-based assays, ELISA, competitive binding, and surface plasmon resonance. Key parameters measured include binding affinity (Kd) and inhibitory concentration (IC50).

Ret Proto-Oncogene

Ret Proto-Oncogene testing identifies mutations and activity levels associated with colon cancer progression, aiding targeted drug development. This service employs HTRF, fluorescent, chemiluminescent, and ATP assays to evaluate compound efficacy. Key parameters measured include minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC-50), providing critical data for optimizing therapeutic candidates and improving treatment outcomes.

Sirtuin 1

Sirtuin 1 (SIRT1) regulates cell survival and metabolism, influencing colon cancer progression and drug response. SIRT1 testing is crucial for identifying therapeutic targets and predicting drug efficacy. Key methods include Western blot, qPCR, and immunohistochemistry to assess SIRT1 expression and activity. Main parameters analyzed are SIRT1 protein levels, mRNA expression, and enzymatic activity, providing valuable insights for colon cancer drug development.